Expression of Biliverdin Reductase A in Peripheral Blood Leukocytes Is Associated with Treatment Response in HCV-Infected Patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10191457" target="_blank" >RIV/00216208:11110/13:10191457 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00023001:_____/13:00058545 RIV/00064165:_____/13:10191457
Výsledek na webu
<a href="http://dx.doi.org/10.1371/journal.pone.0057555" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0057555</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1371/journal.pone.0057555" target="_blank" >10.1371/journal.pone.0057555</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Expression of Biliverdin Reductase A in Peripheral Blood Leukocytes Is Associated with Treatment Response in HCV-Infected Patients
Popis výsledku v původním jazyce
Background and Aims: Hepatitis C virus (HCV) infection is associated with systemic oxidative stress. Since the heme catabolic pathway plays an important role in antioxidant protection, we attempted to assess the gene expression of key enzymes of heme catabolism, heme oxygenase 1 (HMOX1), heme oxygenase 2 (HMOX2), and biliverdin reductase A (BLVRA) in the liver and peripheral blood leukocytes (PBL) of patients chronically infected with HCV. Methods: Gene expressions (HMOX1, HMOX2, BLVRA) and HCV RNA wereanalyzed in PBL of HCV treatment naive patients (n = 58) and controls (n = 55), with a subset of HCV patients having data on hepatic gene expression (n = 35). Based upon the therapeutic outcome, HCV patients were classified as either responders (n = 38)or treatment-failure patients (n = 20). Blood samples in HCV patients were collected at day 0, and week 12, 24, 36, and 48 after the initiation of standard antiviral therapy. Results: Compared to the controls, substantially increased BLV
Název v anglickém jazyce
Expression of Biliverdin Reductase A in Peripheral Blood Leukocytes Is Associated with Treatment Response in HCV-Infected Patients
Popis výsledku anglicky
Background and Aims: Hepatitis C virus (HCV) infection is associated with systemic oxidative stress. Since the heme catabolic pathway plays an important role in antioxidant protection, we attempted to assess the gene expression of key enzymes of heme catabolism, heme oxygenase 1 (HMOX1), heme oxygenase 2 (HMOX2), and biliverdin reductase A (BLVRA) in the liver and peripheral blood leukocytes (PBL) of patients chronically infected with HCV. Methods: Gene expressions (HMOX1, HMOX2, BLVRA) and HCV RNA wereanalyzed in PBL of HCV treatment naive patients (n = 58) and controls (n = 55), with a subset of HCV patients having data on hepatic gene expression (n = 35). Based upon the therapeutic outcome, HCV patients were classified as either responders (n = 38)or treatment-failure patients (n = 20). Blood samples in HCV patients were collected at day 0, and week 12, 24, 36, and 48 after the initiation of standard antiviral therapy. Results: Compared to the controls, substantially increased BLV
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
CE - Biochemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NT13092" target="_blank" >NT13092: Katabolická dráha hemu u chronické hepatitidy C</a><br>
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
PLoS ONE
ISSN
1932-6203
e-ISSN
—
Svazek periodika
8
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
7
Strana od-do
—
Kód UT WoS článku
000316251100011
EID výsledku v databázi Scopus
—